ABBVIE
- Country
- π«π·France
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's Disease
- Conditions
- First Posted Date
- 2016-09-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Registration Number
- NCT02906488
- Locations
- π―π΅
Fukui Red Cross Hospital /ID# 166907, Fukui-shi, Fukui, Japan
π―π΅National Hospital Organization Takasaki General Medical Center /ID# 207773, Takasaki-shi, Gunma, Japan
π―π΅Muroran-Clinic /ID# 207780, Muroran-shi, Hokkaido, Japan
Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa
- First Posted Date
- 2016-09-19
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 15
- Registration Number
- NCT02904902
- Locations
- π―π΅
Fukuoka University Hospital /ID# 151350, Fukuoka, Japan
π―π΅Takagi Dermatological Clinic /ID# 151906, Obihiro, Hokkaido, Japan
π―π΅Kurume University Hospital /ID# 152579, Kurume-shi, Fukuoka, Japan
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
- Conditions
- Interventions
- First Posted Date
- 2016-09-14
- Last Posted Date
- 2024-04-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT02899052
- Locations
- πΊπΈ
Oncology Hematology Associates (OHA) - Springfield /ID# 218855, Springfield, Missouri, United States
πΊπΈUniversity of Pennsylvania /ID# 151768, Philadelphia, Pennsylvania, United States
πΊπΈUniversity of Texas Southwestern Medical Center /ID# 218336, Dallas, Texas, United States
A Study Treating Participants With Early Axial Spondyloarthritis (axSpA) Taking an Intense Treatment Approach Versus Routine Treatment
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2019-07-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 22
- Registration Number
- NCT02897115
Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )
- Conditions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 98
- Registration Number
- NCT02896985
- Locations
- π¨π¦
Columbia Gastro Mgmnt Ltd /ID# 152507, New Westminster, British Columbia, Canada
π¨π¦GIRI Gastrointestinal Research Institute /ID# 201259, Vancouver, British Columbia, Canada
π¨π¦Percuro Clinical Research, Ltd /ID# 202502, Victoria, British Columbia, Canada
Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
- Conditions
- First Posted Date
- 2016-09-12
- Last Posted Date
- 2020-05-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 165
- Registration Number
- NCT02896920
- Locations
- π¨π¦
Alberta DermaSurgery Centre /ID# 153834, Edmonton, Alberta, Canada
π¨π¦Institute for Skin Advancement /ID# 152448, Calgary, Alberta, Canada
π¨π¦Dre. Angelique Gagne-Henley /ID# 152611, St-Jerome, Quebec, Canada
A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 453
- Registration Number
- NCT02880956
- Locations
- πΊπΈ
Irvine Clinical Research /ID# 162331, Irvine, California, United States
πΊπΈBrain Matters Research /ID# 147796, Delray Beach, Florida, United States
πΊπΈNeuropsychiatric Research Center of Southwest Florida /ID# 162332, Fort Myers, Florida, United States
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, Β± Dasabuvir, Β± Ribavirin in Patients With Chronic Hepatitis C in Colombia
- Conditions
- First Posted Date
- 2016-08-01
- Last Posted Date
- 2019-09-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 66
- Registration Number
- NCT02851069
- Locations
- π¨π΄
Centro Medico lmbanaco de Cali I, Cali, Colombia
π¨π΄Fundacion Hospitalaria San Vin, MedellΓn, Colombia
π¨π΄Cic Cali, Cali, Colombia
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2020-03-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT02819999
- Locations
- πΊπΈ
Cleveland Clinic, Cleveland, Ohio, United States
πΊπΈUniversity Hospital of Cleveland, Cleveland, Ohio, United States
πΊπΈRocky Mountain Cancer Centers, Denver, Colorado, United States
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1302
- Registration Number
- NCT02819635
- Locations
- πΊπΈ
The Vancouver Clinic, INC. PS /ID# 162333, Vancouver, Washington, United States
πΊπΈEast View Medical Research, LLC /ID# 171183, Mobile, Alabama, United States
πΊπΈCB Flock Research Corporation /ID# 165980, Mobile, Alabama, United States